Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
4 Masked Men Steal Renoir, Matisse and Cézanne Paintings Worth Over $10 Million in 3-Minute Heist - 22025 Was Another Exceptionally Hot Year
- 310 Setting up camp Shelters That Offer Both Excellence and Isolation
- 4The Most Astonishing Arising Advancements to Watch
- 5Tickets for 'Stranger Things' Season 5 finale, to be shown in movie theaters on New Year's Eve, go on sale today. Here's how you can save your seat.
- Productive CRM Programming for Client Relationship The executives
- Germany's Pistorius: NATO protects Europe from Iranian missiles
- Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- Creative Style: 10 Architects Reclassifying the Business
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- Israeli lawmakers pass bill reviving death penalty for terrorists
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- Famous Places to get-away for Americans
